Compare BBIO & ROKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBIO | ROKU |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 15.9B |
| IPO Year | 2019 | 2017 |
| Metric | BBIO | ROKU |
|---|---|---|
| Price | $74.18 | $110.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 19 |
| Target Price | $76.24 | ★ $115.05 |
| AVG Volume (30 Days) | 2.0M | ★ 3.1M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $353,780,000.00 | ★ $4,543,395,000.00 |
| Revenue This Year | $128.44 | $16.44 |
| Revenue Next Year | $76.14 | $13.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 62.46 | 16.61 |
| 52 Week Low | $25.34 | $52.43 |
| 52 Week High | $76.51 | $116.66 |
| Indicator | BBIO | ROKU |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 65.09 |
| Support Level | $72.73 | $106.47 |
| Resistance Level | $76.51 | $113.40 |
| Average True Range (ATR) | 2.37 | 4.59 |
| MACD | -0.30 | 1.32 |
| Stochastic Oscillator | 66.40 | 88.32 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Roku enables consumers to stream television programming. It has more than 90 million streaming households and provided 127 billion streaming hours in 2024. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.